candesartan has been researched along with hydroxychloroquine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bairey Merz, CN; Berman, DS; Goykhman, P; Ishimori, ML; Mehta, PK; Minissian, M; Shufelt, CL; Thomson, LE; Wallace, DJ; Weisman, MH | 1 |
1 review(s) available for candesartan and hydroxychloroquine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for candesartan and hydroxychloroquine
| Article | Year |
|---|---|
Subendocardial ischemia and myocarditis in systemic lupus erythematosus detected by cardiac magnetic resonance imaging.
Topics: Anti-Inflammatory Agents; Benzimidazoles; Biphenyl Compounds; Chest Pain; Coronary Angiography; Coronary Vessels; Endocardium; Female; Humans; Hydroxychloroquine; Ischemia; Lupus Erythematosus, Systemic; Magnetic Resonance Imaging; Methylprednisolone; Middle Aged; Myocarditis; Tetrazoles; Treatment Outcome | 2012 |